Contineum Therapeutics Inc.
CTNM | NASDAQ
$13.76
+$0.21 (+1.55%)
Sep 22, 2026, 11:24 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 |
|---|---|---|---|---|---|
Revenue | n/a | n/a | 50M | n/a | n/a |
Cost of Revenue | n/a | 258K | n/a | n/a | n/a |
Gross Profit | n/a | -258K | 50M | n/a | n/a |
Operating Income | -68.06M | -50.89M | -16.08M | -22.72M | -28.65M |
Interest Income | 8.25M | 8.91M | 4.61M | 761K | 77K |
Pretax Income | -59.98M | -42.26M | 23.17M | -24.25M | -29M |
Net Income | -59.98M | -42.26M | 22.72M | -24.25M | -29M |
Selling & General & Admin | 16.54M | 12.47M | 6.32M | 5.83M | 6.29M |
Research & Development | 51.52M | 38.16M | 27.6M | 16.89M | 22.36M |
Other Expenses | n/a | n/a | 32.15M | n/a | -91K |
Operating Expenses | 68.06M | 50.64M | 66.08M | 22.72M | 28.65M |
Interest Expense | n/a | n/a | 208K | 388K | 332K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 68.06M | 50.89M | 66.08M | 22.72M | 28.65M |
Income Tax Expense | n/a | n/a | 450K | n/a | n/a |
Shares Outstanding (Basic) | 27.7M | 25.85M | 25.13M | 25.13M | 25.13M |
Shares Outstanding (Diluted) | 27.7M | 25.85M | 25.13M | 25.13M | 25.13M |
EPS (Basic) | -2.17 | -1.63 | 0.13 | -0.97 | -1.15 |
EPS (Diluted) | -2.17 | -1.63 | 0.13 | -0.97 | -1.15 |
EBITDA | -59.66M | -42M | 23.57M | -23.54M | -28.34M |
EBIT | -59.98M | -42.26M | 23.38M | -23.87M | -28.67M |
Depreciation & Amortization | 323K | 258K | 195K | 329K | 325K |
Add to Watchlist
Select watchlists to add or remove CTNM